Strimpakos Alexios Medical OncologistDirector of 5th Internal Medicine - Oncology Clinic HYGEIA
Education & Academic Qualifications
- MRCP (Membership of Royal College of Physicians) 2005
- ATLS (Advanced Trauma Life Support) 2000
- ALS (advanced life support) 2003 &2007
- Good Clinical Practice 2006, 2008, 2013
- Medical School, University of Patras, Greece, 1993-1999
- Medical Oncology Specialty (UK) 2003-2009 (Internal Medicine at Queens Medical Centre, Nottingham; Medical Oncology at The Royal Marsden Hospital, Sutton)
Medical School, University of Athens in 2015
‘‘Alteration of apoptotic and programmed cell death markers after induction of chemotherapy in solid tumors’’
Fellowship in Societies, Membership in Journal Editorial Committees
European Society of Medical Oncology (ESMO) since 2008
American Society of Clinical Oncology (ASCO) since 2009
European Society Digestive Oncology (ESDO) since 2015
Royal College of Physicians (MRCP) since 2005
General Medical Council (GMC-6055877) since 2002
Athens Medical Association (No 057597) since 1999
Clinical Trials and Practice
Has also served as Peer Reviewer in the journals:
Cancer Chemother. Pharmacol. Since Feb 2009
Pharmacogenomics J., since Jun 2009
Annals Of Oncology, since Sept 2010
Cutaneous and Ocular Toxicology. Since March 2012
Therapeutic Advances in Medical Oncology, since March 2012
JOP. Journal of the Pancreas, since October 2012
From January 2019 Medical Oncologist at Hygeia Group (Hygeia & Mitera Hospitals)
November 2016- December 2018: Consultant Medical Oncologist & Director of Dept of Medical Oncology at Athens Medical Center Hospital
July 2015- October 2016: Consultant Medical Oncologist & Director of 4th Dept of Medical Oncology at Euroclinic Athens Hospital
May 2013-June 2015: Senior Clinical Research Fellow in Medical School of Athens and Locum Consultant Medical Oncologist, at the Oncology Unit, 2rd Dept of Medicine, University of Athens, ‘Attikon” General Hospital.
May 2013-June 2015: Senior Clinical Research Fellow in Medical School of Athens and Locum Consultant Medical Oncologist, at the Oncology Unit, 3rd Dept of Medicine, University of Athens, Sotiria General Hospital. Completed the research project – Thesis ‘apoptotic markers in solid tumours following chemotherapy’.
Feb 2006- April 2009: Training in Med. Oncology at The Royal Marsden Hospital, London UK.
Dec 2002– Feb 2006: SHO in Medicine, United K
Jul 2001 – Oct 2002: Resident in the Emergency Dept at the Kyparissia’s Hospital, Greece.
Nov 1999 – May 2001: Military in the Greek army (National Service).
2009-2015 Regular teaching and tutoring of Undergraduate Medical Students of the University of Athens at Sotiria General Hospital and “Attikon” University Hospital
2009-2015 Teaching and tutoring of Internal Medicine Residents at Sotiria General Hospital and “Attikon” University Hospital
2013-2015 Teaching and tutoring of Medical Oncology Residents at “Attikon” University Hospital
2010-2013 Teaching in Postgraduate Students undertaking Master of Science projects in the University of Athens
Clinical & Research Interest
All types of Solid tumours with special focus to Gastrointestinal Cancers, Aerodigestive cancers, Lung Cancer, Breast Cancer, Urological cancers and Palliative Care
Gastrointestinal Cancers, Lung Cancer, Personalized and Translational Medicine
Honors & Awards
Educational Grant from Hellenic society of Medical Oncology for the research project «Alteration of apoptotic and programmed cell death markers after induction of chemotherapy in solid tumors”. (2010)
HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. Anticancer Res. 2016 Apr;36(4):1581-90.
Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. Oncology. 2015;89(1):53-9.
Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol. 2013 Nov;72(5):935-52.
The clinical significance of cytology versus histology-based diagnosis in small cell lung cancer: a retrospective study. Lung Cancer. 2014
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2013 Dec;12(4):267-274
Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. Oncology. 2015 Feb 28
HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. Anticancer Res. 2016 Apr;36(4):1581-90
«The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy». Ann Oncol. 2009 Oct 27
“ Pharmacogenetics and biomarkers in Colorectal cancer”. The Pharmacogenomics J. 2009 Jun;9(3):147-60
Comprehensive review: Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials. Antioxid Redox Signal.2008, Mar;10(3): 511-45 (>540 citations)
List of publications (>870 Citations)